|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Levetiracetam in Patients with Refractory Epilepsy: Results of the SKATE Trial in Austria, Germany and Switzerland显示文摘 | Steinhoff BJ Trink E Wieser HG | 2005 | Seizure (S1059 - 1311 )2005，14，7： | 1 |
| 2 | The Akt-specific inhibitorMK2206 selectively inhibits thyroid cancer cells harboringmutations that can activate the PI3 K/Akt pathway 显示文摘 | Liu R Liu D Trink E | 2011 | J ClinEndocrinol Metab2011，96，4： | 1 |
| 3 | The Akt-specifie inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway 显示文摘 | Liu R Liu D Trink E | 2011 | J Clin Endoefinol MeTab2011，96，4： | 1 |
| 4 | acrylophenones : Potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase显示文摘 | Traxler P Trinks U Buchdunger E | 1995 | J Med Chem1995，38，： | 1 |
| 5 | 4,5-Bis(4-fluoroanilino) phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity 显示文摘 | Buchdunger E Mett H Trinks U | 1995 | Clin Cancer Res1995，1，8： | 1 |
| 6 | A randomized,doubleblind,placebo-and active-controlled,half-head study to evaluate the effects of platelet-rich plasma on alopecia areata显示文摘 | Trink A Sorbellini E Bezzola P | 2013 | Br J Dermatol2013，169，3： | 1 |
| 7 | p63 transcriptional regulation of epithelial integrity and cancer显示文摘 | Trink B Osada M Ratovitski E | 2007 | Cell Cycle2007，6，3： | 1 |
| 8 | Dianilinophthalimides:potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase显示文摘 | Trinks U Buchdunger E Furet P | 1994 | J Med Chem1994，37，7： | 1 |
| 9 | 4, 5-Dis(4-fluoroanilino) phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity显示文摘 | Buchdunger E Mett H Trinks U | 1995 | Clin Cancer Res1995，1，8： | 1 |
| 10 | p63 transcriptional regulation of epithelial integrity and cancer显示文摘 | Trink B Osada M Ratovitski E | 2007 | Cell Cycle2007，6，： | 1 |
| 11 | A randomized, double -blind, placebo- and active-controlled, half-head study to evaluatethe effects of platelet -rich plasma on alopecia areata 显示文摘 | Trink A Sorbellini E Bezzola P | 2013 | Br JDermatol2013，169，3： | 1 |
| 12 | Levetiracetam in patients with refractory epilepsy:Results of the SKATE trial in Austria, Germany and Switzerland 显示文摘 | Steinhoff BJ Trink E Wieser HG | 2005 | Seizure2005，14，7： | 1 |
| 13 | Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3显示文摘AIM: To evaluate pre-treatment factors associated with sustained virological response(SVR) in patients with hepatitis C virus(HCV) genotype 3 treated with peginterferon and ribavirin(RBV). METHODS: We retrospectively analyzed treatment naive, mono-infected HCV genotype 3 patients treated with peginterferon and RBV. Exclusion criteria included presence of other liver disease, alcohol consumption and African American or Asian ethnicity. The variables collected and compared between patients who achieved an SVR and patients who did not were as follows: gender, age, fibrosis stage, diabetes, body mass index,steatosis, INFL3 polymorphism, pre-treatment HCVRNA, type of peginterferon, RBV dose and adherence. RESULTS: A total of 107 patients treated between June, 2004 and March, 2013 were included. Mean treatment duration was 25.1(± 1.8) wk. Overall, 58%(62/107) of the patients achieved an SVR and 42%(45/107) did not. In the multivariate logistic regression analysis, pre-treatment HCV-RNA ≥ 600000 UI/m L(OR = 0.375, 95%CI: 0.153-0.919, P = 0.032) and advanced fibrosis(OR = 0.278, 95%CI: 0.113-0.684,P = 0.005) were significantly associated with low SVR rates. In patients with pre-treatment HCV-RNA ≥600000 UI/m L and advanced fibrosis, the probability of achieving an SVR was 29%(95%CI: 13.1-45.2).In patients with pre-treatment HCV-RNA < 600000UI/m L and mild to moderate fibrosis, the probability of achieving an SVR was 81%(95%CI: 68.8-93.4).CONCLUSION: In patients with HCV genotype 3infections the presence of advance fibrosis and high pre-treatment viral load might be associated with poor response to peginterferon plus RBV. These patients could benefit the most from new direct antiviral agentsbased regimes. | Sebastian Marciano Silvia M Borzi Melisa Dirchwolf Ezequiel Ridruejo Manuel Mendizabal Fernando Bessone Maria E Sirotinsky Diego H Giunta Julieta Trinks Pablo A Olivera Omar A Galdame Marcelo O Silva Hugo A Fainboim Adrian C Gadano | 2015 | World Journal of Hepatology2015，7，4： | 1 |
| 14 | CSI-EPT:A Contrast Source Inversion Approach for Improved MRI-Based Electric Properties Tomography显示文摘 | Balidemaj E Van Den berg CA Trinks J | 2015 | IEEE Transactions on Medical Imaging2015，34，9： | 1 |
| 15 | Levetiracetam in patients with refractory epilepsy : Results of the SKATE trial in Austria, Germany and Switzerland 显示文摘 | Steinhof B J Trink E Wieser HG | 2005 | Seizure2005，14，49： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员